Kutty Preeta K, Jain Seema, Diaz Maureen H, Self Wesley H, Williams Derek, Zhu Yuwei, Grijalva Carlos G, Edwards Kathryn M, Wunderink Richard G, Winchell Jonas, Hicks Lauri A
Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
California Department of Public Health, California, USA.
Int J Med Sci. 2024 Nov 11;21(15):3003-3009. doi: 10.7150/ijms.99233. eCollection 2024.
The burden and epidemiology of (Mp) community-acquired pneumonia (CAP) among hospitalized U. S. adults (≥ 18 years) are poorly understood. In the Etiology of Pneumonia in the Community (EPIC) study, we prospectively enrolled 2272 adults hospitalized with radiographically-confirmed pneumonia between January 2010-June 2012 and tested nasopharyngeal/oropharyngeal swabs for Mp by real-time polymerase chain reaction (PCR). Clinical and epidemiological features of Mp-PCR-positive and -negative adults were compared using logistic regression. Macrolide susceptibility was assessed by genotyping isolates. Among 2272 adults, 43 (1.8%) were Mp-PCR-positive (median age: 45 years); 52% were male, and 56% were non-Hispanic white. Only one patient had Mp macrolide resistance. Four (9%) were admitted to the intensive care unit (ICU). No in-hospital deaths were reported. Of the 9 (21%) who received an outpatient antibiotic ≤5 days pre-admission, 2 (22%) received an antibiotic with Mp activity. Variables significantly associated with higher odds of Mp detection included age {18-29 years [(adjusted odds ratio (aOR): 11.7 (95% confidence interval (CI): 5.1- 26.6) versus ≥50 years]} and radiographic lymphadenopathy [aOR: 3.5 (95% CI: 1.2- 9.3)]. , commonly known to cause "walking pneumonia", was detected among hospitalized adults, with the highest prevalence among young adults. Although associated with clinically non-specific symptoms, approximately one out of every ten patients were admitted to the ICU. Increasing access to point-of-care testing could facilitate targeted treatment and avoid hospitalization.
美国≥18岁住院成人中肺炎支原体(Mp)社区获得性肺炎(CAP)的负担及流行病学情况尚不清楚。在社区肺炎病因(EPIC)研究中,我们前瞻性纳入了2010年1月至2012年6月间因影像学确诊肺炎而住院的2272名成人,并通过实时聚合酶链反应(PCR)检测鼻咽/口咽拭子中的Mp。使用逻辑回归比较Mp-PCR阳性和阴性成人的临床和流行病学特征。通过对分离株进行基因分型评估大环内酯类药物敏感性。在2272名成人中,43例(1.8%)Mp-PCR阳性(中位年龄:45岁);52%为男性,56%为非西班牙裔白人。仅1例患者存在Mp大环内酯类耐药。4例(9%)入住重症监护病房(ICU)。未报告院内死亡病例。在入院前≤5天接受门诊抗生素治疗的9例(21%)患者中,2例(22%)接受了对Mp有活性的抗生素。与Mp检测几率较高显著相关的变量包括年龄{18 - 29岁[(调整优势比(aOR):11.7(95%置信区间(CI):5.1 - 26.6)与≥50岁相比]}和影像学显示的淋巴结病[aOR:3.5(95%CI:1.2 - 9.3)]。肺炎支原体通常被认为可引起 “迁延性肺炎”,在住院成人中被检测到,在年轻人中患病率最高。尽管与临床非特异性症状相关,但每十名患者中约有一名入住ICU。增加即时检测的可及性有助于进行针对性治疗并避免住院。